APA, Others Seek FDA Forum on REMS

Multiple psychiatric groups have asked the US Food and Drug Administration (FDA) to consider holding a public meeting about its approach to risk management of the schizophrenia drug clozapine, which is effective but carries serious risks, including death. In a February 14 letter, the groups asked the FDA to reconsider its new risk evaluation and … Read more